Visterra, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Boston MA United States (2007)
Status: Acquired by Otsuka (2018)

Organization Overview

First Clinical Trial
2014
NCT02045472
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Visterra, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

oseltamivir (tamiflu) (1 trial)

vis410 (4 trials)

vis649 (2 trials)

Drugs in Phase 1 Trials (1)

vis171 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glomerulonephritis, IGA (Phase 2)

Influenza, Human (Phase 2)

Kidney Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 4